Advertisement

Drug Excipient Interactions

  • Ajit S. NarangEmail author
  • Aaron Yamniuk
  • Limin Zhang
  • S. Nilgun Comezoglu
  • Dilbir S. Bindra
  • Sailesh A. Varia
  • Michael Doyle
  • Sherif Badawy
Chapter

Abstract

Unintended physicochemical interaction of an excipient with a drug substance in a dosage form can result in the complexation or binding of the drug, resulting in slow and/or incomplete drug release in a dissolution medium. It is important to assess the risk whether such interactions would reduce oral bioavailability of a drug from its dosage form. This chapter describes the development of a methodology to assess the biorelevance of the drug release impact of drug-excipient binding interactions using a model compound, brivanib alaninate. This methodology was developed using a combination of modeling and simulation tools as well as experimental data generated in vitro and in vivo. In addition, general application of this principle and methodology to other drug substances and binding affinities of drugs with excipients as a function of dose is described.

Keywords

Adsorption Bioavailability Binding Brivanib alaninate Croscarmellose sodium Excipient Isothermal titration calorimetry Langmuir adsorption isotherm Wet granulation 

Abbreviations

AUC0−t

Area under the plasma concentration-time curve from dosing till time of last sampling (72 h)

BA

Brivanib alaninate

CCS

Croscarmellose sodium

Cmax

Maximum concentration reached in plasma

HPLC

High performance liquid chromatography

HPMC

Hydroxypropyl methyl cellulose

ITC

Isothermal titration calorimetry

NMR

Nuclear magnetic resonance

SSG

Sodium starch glycollate

t½

Plasma half life

Tmax

The time of maximum plasma concentration

USNF

United States National Formulary

Vd

Volume of distribution

xPVP

Crospovidone

Notes

Acknowledgements

We thank our biostatistics colleague, James Bergum, for help with statistical analyses of data. The majority of this chapter and illustrations are reprinted from Journal of Pharmacy and Pharmacology, Vol 64 (© 2012) pp 553–565, with permission from John Wiley and Sons.

References

  1. Aideloje SO, Onyeji CO, Ugwu NC (1998) Altered pharmacokinetics of halofantrine by an antacid, magnesium carbonate. Eur J Pharm Biopharm 46(3):299–303CrossRefPubMedGoogle Scholar
  2. Al-Duri B, Yong YP (1997) Characterization of the equilibrium behavior of lipase PS (from Pseudomonas) and lipolase 100 L (from Humicola) onto Accurel EP100. J Mol Catal B Enzym 3 (1–4):177–188CrossRefGoogle Scholar
  3. Balasubramaniam J, Bindu K, Rao VU, Ray D, Haldar R, Brzeczko AW (2008) Effect of superdisintegrants on dissolution of cationic drugs. Dissolution Technol 15(2):18–25CrossRefGoogle Scholar
  4. Caldwell GW, Yan Z (2004) Isothermal titration calorimetry characterization of drug-binding energetics to blood proteins. In: Yan Z, Caldwell GW (eds), Methods in pharmacology and toxicology optimization in drug discovery: In vitro methods, Humana Press, Inc., Totowa, NJ, pp 123–149Google Scholar
  5. Chien YW, Van Nostrand P, Hurwitz AR, Shami EG (1981) Drug–disintegrant interactions: binding of oxymorphone derivatives. J Pharm Sci 70(6):709–710CrossRefPubMedGoogle Scholar
  6. Dhanaraju MD, Kumaran KS, Baskaran T, Moorthy MS (1998) Enhancement of bioavailability of griseofulvin by its complexation with beta-cyclodextrin. Drug Dev Ind Pharm 24(6):583–587CrossRefPubMedGoogle Scholar
  7. Doyle ML (1997) Characterization of binding interactions by isothermal titration calorimetry. Curr Opin Biotechnol 8(1):31–35CrossRefPubMedGoogle Scholar
  8. Dressman JB, Berardi RR, Dermentzoglou LC, Russell TL, Schmaltz SP, Barnett JL, Jarvenpaa KM (1990) Upper gastrointestinal (GI) pH in young, healthy men and women. Pharm Res 7(7):756–761CrossRefPubMedGoogle Scholar
  9. Fransen N, Morin M, Bjork E, Edsman K (2008) Physicochemical interactions between drugs and superdisintegrants. J Pharm Pharmacol 60(12):1583–1589CrossRefPubMedGoogle Scholar
  10. Healy DP, Dansereau RJ, Dunn AB, Clendening CE, Mounts AW, Deepe GS Jr (1997) Reduced tetracycline bioavailability caused by magnesium aluminum silicate in liquid formulations of bismuth subsalicylate. Ann Pharmacother 31(12):1460–1464PubMedGoogle Scholar
  11. Hollenbeck RG (1988) Bioavailability of phenylpropanolamine hydrochloride from tablet dosage forms containing croscarmellose sodium. Int J Pharm 47(1–3):89–93CrossRefGoogle Scholar
  12. Hollenbeck RG, Mitrevej KT, Fan AC (1983) Estimation of the extent of drug-excipient interactions involving croscarmellose sodium. J Pharm Sci 72(3):325–327CrossRefPubMedGoogle Scholar
  13. Huang WX, Desai M, Tang Q, Yang R, Vivilecchia RV, Joshi Y (2006) Elimination of metformin-croscarmellose sodium interaction by competition. Int J Pharm 311(1–2):33–39CrossRefPubMedGoogle Scholar
  14. Hughes GS, Heald DL, Barker KB, Patel RK, Spillers CR, Watts KC, Batts DH, Euler AR (1989) The effects of gastric pH and food on the pharmacokinetics of a new oral cephalospoin, cefpodoxime proxetil. Clin Pharmacol Ther 46(6):674–685CrossRefPubMedGoogle Scholar
  15. van Hullebusch ED, Gieteling J, Zhang M, Zandvoort MH, Daele WV, Defrancq J, Lens PN (2006) Cobalt sorption onto anaerobic granular sludge: isotherm and spatial localization analysis. J Biotechnol 121(2):227–240CrossRefPubMedGoogle Scholar
  16. Huynh H, Ngo VC, Fargnoli J, Ayers M, Soo KC, Koong HN, Thng CH, Ong HS, Chung A, Chow P, Pollock P, Byron S, Tran E (2008) Brivanib alaninate, a dual inhibitor of vascular endothelial growth factor receptor and fibroblast growth factor receptor tyrosine kinases, induces growth inhibition in mouse models of human hepatocellular carcinoma. Clin Cancer Res 14(19):6146–6153CrossRefPubMedGoogle Scholar
  17. Jahr JS, Burckart G, Smith SS, Shapiro J, Cook DR (1991) Effects of famotidine on gastric pH and residual volume in pediatric surgery. Acta Anaesthesiol Scand 35(5):457–460CrossRefPubMedGoogle Scholar
  18. Jantratid E, Janssen N, Reppas C, Dressman JB (2008) Dissolution media simulating conditions in the proximal human gastrointestinal tract: an update. Pharm Res 25(7):1663–1676CrossRefPubMedGoogle Scholar
  19. Jelesarov I, Bosshard HR (1999) Isothermal titration calorimetry and differential scanning calorimetry as complementary tools to investigate the energetics of biomolecular recognition. J Mol Recognit 12(1):3–18CrossRefPubMedGoogle Scholar
  20. Jeong SH, Park K (2008) Drug loading and release properties of ion-exchange resin complexes as a drug delivery matrix. Int J Pharm 361(1–2):26–32CrossRefPubMedGoogle Scholar
  21. Kaukonen AM, Lennernas H, Mannermaa J-P (1998) Water-soluble b-cyclodextrins in pediatric oral solutions of spironolactone: preclinical evaluation of spironolactone bioavailability from solutions of b-cyclodextrin derivatives in rats. J Pharm Pharmacol 50(6):611–619CrossRefPubMedGoogle Scholar
  22. Kedzierewicz F, Zinutti C, Hoffman M, Maincent P (1993) Bioavailability study of tolbutamide b-cyclodextrin inclusion compounds, solid dispersions and bulk powder. Int J Pharm 94(1–3):69–74CrossRefGoogle Scholar
  23. LeVan MD, Vermeulen T (1981) Binary Langmuir and Freundlich isotherms for ideal adsorbed solutions. J Phys Chem 85(22):3247–3250CrossRefGoogle Scholar
  24. Lovatt M, Cooper A, Camilleri P (1996) Energetics of cyclodextrin-induced dissociation of insulin. Eur Biophys J 24(5):354–357CrossRefPubMedGoogle Scholar
  25. Mahore JG, Wadher KJ, Umekar MJ, Bhoyar PK (2010) Ion exchange resins: pharmaceutical applications and recent advancement. Int J Pharm Sci Review Res 1(2):8–13Google Scholar
  26. McPhail D, Cooper A (1997) Thermodynamics and kinetics of dissociation of ligand-induced dimers of vancomycin antibiotics. J Chem Soc Faraday Trans 93(13):2283–2289CrossRefGoogle Scholar
  27. Moore JW, Flanner HH (1996) Mathematical comparison of curves with an emphasis on in-vitro dissolution profiles. Pharm Technol 20:64–74Google Scholar
  28. Narang AS, Rao VM, Raghavan K (2009) Excipient compatibility. In: Qiu Y, Chen Y, Zhang GGZ, Liu L, Porter W (eds) Developing solid oral dosage forms: pharmaceutical theory and practice. Elsevier, Burlington, p 125–146CrossRefGoogle Scholar
  29. Narang AS et al (2012). Reversible and pH-dependent weak drug-excipient binding does not affect oral bioavailability of high dose drugs. J Pharm Pharmacol 64(4):553–565Google Scholar
  30. Otero-Espinar FJ, Anguiano-Igea S, Garcia-Gonzalez N, Vila-Jato JL, Blanco-Mendez J (1991) Oral bioavailability of naproxen-b-cyclodextrin inclusion compound. Int J Pharm 75(1):37–44CrossRefGoogle Scholar
  31. Poon GMK (2010) Explicit formulation of titration models for isothermal titration calorimetry. Anal Biochem 400(2):229–236CrossRefPubMedGoogle Scholar
  32. Raghunathan Y, Amsel L, Hinsvark O, Bryant W (1981) Sustained-release drug delivery system I: coated ion-exchange resin system for phenylpropanolamine and other drugs. J Pharm Sci 70(4):379–384CrossRefPubMedGoogle Scholar
  33. The United States pharmacopeial convention (2010) Croscarmellose sodium. In: United States pharmacopeia—national formulary (USP 32– NF 27). US Government, Washington, DCGoogle Scholar
  34. Velazquez-Campoy A, Kiso Y, Freire E (2001) The binding energetics of first- and second-generation HIV-1 protease inhibitors: implications for drug design. Arch Biochem Biophys 390(2):169–175CrossRefPubMedGoogle Scholar
  35. Woods JM, Puri M, Doucet D, Derrick T, Morar-Mitrica S, Nesta D (2009) Applications of isothermal titration calorimetry and differential scanning calorimetry in biopharmaceutical formulation development. GE Healthc Appl Note 28(9613):26AA21–26AA26Google Scholar

Copyright information

© Springer International Publishing Switzerland 2015

Authors and Affiliations

  • Ajit S. Narang
    • 1
    Email author
  • Aaron Yamniuk
    • 3
  • Limin Zhang
    • 2
  • S. Nilgun Comezoglu
    • 4
  • Dilbir S. Bindra
    • 1
  • Sailesh A. Varia
    • 1
  • Michael Doyle
    • 3
  • Sherif Badawy
    • 1
  1. 1.Drug Product Science and TechnologyBristol-Myers Squibb, Co.New BrunswickUSA
  2. 2.Analytical and Bioanalytical DevelopmentBristol-Myers Squibb, Co.New BrunswickUSA
  3. 3.Gene Expression and Protein Biochemistry DepartmentBristol-Myers Squibb, Co.PrincetonUSA
  4. 4.Biotransformation DepartmentBristol-Myers Squibb, Co.PrincetonUSA

Personalised recommendations